LexDanaLexDanabeta
Inventor

Zhe Wang

Inventor
Hockessin, DE, US

Overview

82→
Patents
1994–2021
Patent span
Chemistry
Primary field (CPC C)

Patents· 82 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations23%
C07DHeterocyclic compounds21%
A61KPreparations for medical, dental or toiletry purposes18%
C07KPeptides17%
C07HSugars5%
C07CAcyclic or carbocyclic compounds4%
Y02PClimate change mitigation technologies in the production or processing of goods2%
C12NMicroorganisms or enzymes1%
C10MLubricating compositions1%
C10NIndexing scheme associated with subclass c10m relating to lubricating compositions1%
PatentTitleYear
10,886,789Method of foreign object detection and foreign object detection device202110,752,934PQQ-sGDH mutant, polynucleotide and glucose detection biosensor202010,709,729Compositions and methods for inhibiting expression of ADAMTS-5 and ADAM17202010,392,351Method for preparing nilotinib intermediate20199,944,860Methods for treating a metathesis feedstock with metal alkoxides20189,550,781'Kinase modulating compounds, compositions containing the same and use thereof'20179,526,769'Macrocylic oximyl hepatitis C protease inhibitors'20169,481,850'Maleinized ester derivatives'20169,464,255'Maleinized ester derivatives'20169,458,170'Compound of camptothecin and preparation and use thereof'20169,242,974'Processes for the preparation of 2-fluoro 6-11 bicyclic erythromycin derivatives'20169,133,258'Myomegalin variant 8'20158,962,551'Quinoxalinyl derivatives'20158,951,998'Quinoxaline-containing compounds as hepatitis C virus inhibitors'20158,940,688'Fluorinated tripeptide HCV serine protease inhibitors'20158,835,376'Process for making particles for delivery of drug nanoparticles'20148,809,264'Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors'20148,785,377'Tetrazolyl macrocyclic hepatitis C serine protease inhibitors'20148,552,162'Processes for the preparation of 2 fluoro 6-11 bicyclic erythromycin derivatives'20138,501,681'Macrocyclic hepatitis C virus serine protease inhibitors'20138,501,682'Difluorinated tripeptides as HCV serine protease inhibitors'20138,466,296'Compounds and processes for preparing substituted aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-ones'20138,426,360'Carbocyclic oxime hepatitis C virus serine protease inhibitors'20138,383,583'Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors'20138,377,872'Cyclic P3 tripeptide hepatitis C serine protease inhibitors'20138,372,802'Fluorinated macrocyclic compounds as hepatitis C virus inhibitors'20138,361,958'Oximyl HCV serine protease inhibitors'20138,324,155'Quinoxaline-containing compounds as hepatitis C virus inhibitors'20128,304,385'Macrocyclic tetrazolyl hepatitis C serine protease inhibitors'20128,283,309'Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors'20128,273,709'Triazole-containing macrocyclic HCV serine protease inhibitors'20128,268,777'Oximyl macrocyclic derivatives'20128,268,776'Macrocylic oximyl hepatitis C protease inhibitors'20128,263,549'C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors'20128,236,807'Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors'20128,222,203'Macrocyclic oximyl hepatitis C serine protease inhibitors'20128,211,891'Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors'20128,193,346'Process for making macrocyclic oximyl hepatitis C protease inhibitors'20128,124,584'Macrocyclic hepatitis C serine protease inhibitors'20128,101,567'Heteroaryl-containing tripeptide HCV serine protease inhibitors'20128,030,307'Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease'2011RE042375'Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors'20117,919,627'Processes for the preparation of hydroxylamines'20117,910,587'Quinoxalinyl dipeptide hepatitis C virus inhibitors'20117,906,513'Hydrazide-containing hepatitis C serine protease inhibitors'20117,842,813'Processes for the preparation of O-[5-(4-amino-thiazol-2-yl)-pyridin-2-ylmethyl]-hydroxylamine'20107,728,148'Acyclic oximyl hepatitis C protease inhibitors'20107,718,612'Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors'20107,718,769'Tri-peptide hepatitis C serine protease inhibitors'20107,687,459'Arylalkoxyl hepatitis C virus protease inhibitors'20107,662,779'Triazolyl macrocyclic hepatitis C serine protease inhibitors'20107,635,683'Quinoxalinyl tripeptide hepatitis C virus inhibitors'20097,605,126'Acylaminoheteroaryl hepatitis C virus protease inhibitors'20097,601,709'Macrocyclic hepatitis C serine protease inhibitors'20097,582,605'Phosphorus-containing hepatitis C serine protease inhibitors'20097,566,719'Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors'20097,563,877'Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182'20097,538,225'Processes for the preparation of o-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine'20097,517,859'Spirocyclic bicyclolides'20097,419,962'3,6-bicyclolides'20087,414,030'6-11 Bicyclic erythromycin derivatives'20087,407,942'3,6-bridged 9,12-oxolides'20087,384,921'Polymorphic forms of 6-11 bicyclic ketolide derivatives'20087,368,452'Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors'20087,312,201'Tetracyclic bicyclolides'20077,291,602'11,12-lactone bicyclolides'20077,273,851'Tri-peptide hepatitis C serine protease inhibitors'20077,265,094'9N-substituted 6-11 bicyclic erythromycin derivatives'20077,229,972'3,6-Bicyclolides'20077,176,208'Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors'20077,135,573'Processes for the preparation of O-(6-Pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine'20067,125,845'Aza-peptide macrocyclic hepatitis C serine protease inhibitors'20067,022,679'Processes for the preparation of 6-11 bicyclic erythromycin derivatives'20066,562,963'Process for the preparation of macrocyclic metalloprotease inhibitors'20036,359,164'Process for the preparation of cyclopropylacetylene'20026,307,044'Process for the preparation of macrocyclic metalloprotease inhibitors'20016,297,410'Process for the preparation of cyclopropylacetylene'20016,288,297'Process for the preparation of cyclopropylacetylene'20016,121,272'Bidentate metalloprotease inhibitors'20006,049,019'Process for the preparation of cyclopropylacetylene'20006,015,912'Spirocyclic containing hydroxamic acids useful as metalloprotease inhibitors'20005,332,811'Etopside analogs'1994

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2000–2016Based in Hockessin, DE, US· patent location history
2006–2016Patents assigned to ENANTA PHARM INC (60)· patent assignee history
2012–2016Patents assigned to WANG ZHE (28)· patent assignee history
2012–2016Patents assigned to OR YAT SUN (26)· patent assignee history
2012–2015Patents assigned to GAI YONGHUA (13)· patent assignee history
2012–2016Patents assigned to SUN YING (12)· patent assignee history
2016–2018Based in Aurora, IL, US· patent location history
2016–2017Based in Beijing, CN· patent location history
2020Based in Zhejiang, CN· patent location history
2021Based in Lugong, TW· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
ENANTA PHARM INC602006–2016
WANG ZHEself282012–2016
OR YAT SUN262012–2016
GAI YONGHUA132012–2015
SUN YING122012–2016
Locations
LocationPatentsSpan
Hockessin, Delaware, US682000–2016
Aurora, Illinois, US22016–2018
Beijing, CN22016–2017
Lugong, TW12021
Zhejiang, CN12020